# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Acute myeloid leukemia

Acute Non Lymphoblastic Leukemia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 71-80 of 631 results.
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Status: Not yet recruiting
Last Changed: May 16, 2019
First Received: May 16, 2019
Disease(s): Acute Myeloid Leukemia, Adult
Intervention(s): Midostaurin
Locations: Universitätsklinikum Jena, Jena, Germany
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
Status: Recruiting
Last Changed: Feb 06, 2018
First Received: Sep 18, 2012
Disease(s): Acute Myeloid Leukemia
Intervention(s): DC vaccine
Locations: ZNA Stuivenberg, Antwerp, Belgium
Antwerp University Hospital, Antwerp, Belgium
University Hospital Brussels, Brussels, Belgium
Cliniques Universitaires Saint-Luc, Brussel, Belgium
Ghent University Hospital, Ghent, Belgium
... and 4 other locations.
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Status: Recruiting
Last Changed: Sep 17, 2019
First Received: Apr 30, 2018
Disease(s): Acute Myeloid Leukemia (AML)
Intervention(s): Midostaurin, Midostaurin Placebo, Chemotherapy
Locations: Community Cancer Institute, Clovis, California, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Oregon Health and Science University, Portland, Oregon, United States
Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah, United States
... and 151 other locations.
Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Jan 29, 2019
First Received: Feb 02, 2015
Disease(s): Recurrent Adult Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Intervention(s): MEN1112
Locations: ZNA Stuivenberg, Antwerp, Belgium
Bruxelles, Belgium
Liège, Belgium
Yvoir, Belgium
Lille, France
... and 17 other locations.
CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Mar 13, 2019
First Received: Jun 15, 2018
Disease(s): Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Intervention(s): FMS Inhibitor JNJ-40346527, Pharmacokinetic Study
Locations: OHSU Knight Cancer Institute, Portland, Oregon, United States
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Status: Not yet recruiting
Last Changed: Apr 17, 2019
First Received: Dec 05, 2018
Disease(s): Relapsed or Refractory Acute Myeloid Leukemia
Intervention(s): Dexamethasone, Amsacrine, Cytarabine, Azacitidine
Locations: CHU de Grenoble, Grenoble, France
CHU de Limoges, Limoges, France
Institut Paoli Calmettes, Marseille, France
CHU de Montpellier, Montpellier, France
CHU de Nantes, Nantes, France
... and 4 other locations.
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
Status: Recruiting
Last Changed: Mar 20, 2019
First Received: Oct 05, 2018
Disease(s): Acute Myeloid Leukemia in Remission
Intervention(s): DCP-001
Locations: Universitats Klinikum Bonn, Bonn, Germany
Universitats Klinikum Leipzig, Leipzig, Germany
Universitätsmedizin Mainz, Mainz, Germany
VUmc, Amsterdam, Netherlands
UMCG, Groningen, Netherlands
... and 1 other locations.
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Sep 06, 2019
First Received: Jan 04, 2018
Disease(s): Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Intervention(s): Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Avelumab, Azacitidine, Gemtuzumab Ozogamicin, Glasdegib, Glasdegib Maleate, Venetoclax, Azacitidine
Locations: M D Anderson Cancer Center, Houston, Texas, United States
CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Jun 14, 2019
First Received: Jun 13, 2019
Disease(s): Acute Myeloid Leukemia, Relapsed, Adult
Intervention(s): CDIAG regimen
Locations: The First Affliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Status: Recruiting
Last Changed: Feb 12, 2019
First Received: Oct 29, 2018
Disease(s): Acute Myeloid Leukemia (AML)
Intervention(s): Quizartinib
Locations: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China